UPDATE -- Clinipace Worldwide Executive Joins Board of Kidney Health Initiative 

Chief Business Officer Hampton Corley Welcomes Opportunity Advance Nephrology Research

Print
| Source: Clinipace Worldwide

MORRISVILLE, N.C., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Hampton Corley, Chief Business Officer of Clinipace Worldwide, a global full-service clinical research organization (CRO), has been appointed to the Board of Directors of the American Society of Nephrology’s Kidney Health Initiative (KHI).  Corley will serve on the Board for a renewable three-year term from January 1, 2018, to December 31, 2020.

“I welcome this opportunity to support the efforts of the KHI,” said Corley. “Our company endorses the initiative’s mission of advancing scientific understanding of the kidney health and patient safety implications of new and existing medical products, and therapy development for kidney disease – an area of great unmet need.”  

“Nephrology is a key therapeutic area for Clinipace going forward,” said Eric B. Grossman, MD, Vice President and Medical Director of Clinipace Worldwide. “We especially support the KHI’s efforts to create a collaborative environment in which sponsors, regulators, Principal Investigators and the greater nephrology community can interact to optimize evaluation of therapies.”

Clinipace will attend the KHI Open House on Friday, November 3, in New Orleans, during the ASN Kidney Week.

About Clinipace Worldwide 
Clinipace Worldwide, a global full-service clinical research organization (CRO) serves the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms, helping them advance drug candidates to deliver successful stakeholder and patient outcomes. The company leverages extensive therapeutic knowledge and clinical trial expertise to support life science firms in achieving some of their most important goals: executing regulatory strategies, optimizing clinical development timelines and completing high quality trials. Committed to delivering against timelines and milestone events, Clinipace has completed more than 1,500 clinical trials and 1,500 regulatory and statistical consulting projects and operates in North America, South America, Europe, and Asia.  To learn more, visit www.clinipace.com.

Media Contact: 
Sandra Parrish Woodlief 
919-797-9480